- Thursday, October 13
- 10:45 AM - 11:45 AM
This clinically focused session will address many important questions regarding the management of elevated triglycerides with the goal of providing practical guidance to manage patients at high CV risk. The expert faculty will compare data on safety, tolerability, and the cardioprotective benefits of the various treatment strategies available.
Describe the causal association between triglycerides (TG), TG-rich lipoproteins (TRL), TRL remnants, and significant increased risk of major adverse cardiovascular events
Explain the role of omega-3 fatty acids, particularly icosapent ethyl, on reducing the risk of major adverse cardiovascular events in patients with hypertriglyceridemia
Screen, diagnose, and manage patients with hypertriglyceridemia who are at high risk of cardiovascular events based on professional society guidelines and recent large-scale randomized clinical trial evidence
Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology and Past President of the National Lipid Association. He is a Fellow of the National Lipid Association , President of the American Board of Clinical Lipidology & Vice Presiden...
Matthew Jay Budoff, MD, FACC, FAHA, is a professor of medicine at David Geffen School of Medicine at UCLA and the Endowed Chair of Preventive Cardiology at Harbor-UCLA Medical Center. Dr. Budoff is a graduate of University of California at Riverside ...